CEO Sang Joon Park highlights the role of medical imaging AI in international health collaboration

October 1, 2026 | Health News

MEDICAL IP CEO Sang Joon Park participated in the 2026 Concordia Annual Summit in New York on September 22, during the week of the United Nations General Assembly. He joined a panel titled “Beyond K-Pop: How Korean Innovation Can Shape the Future of Global Health,” where participants discussed how Korean technologies can contribute to global health and how to improve access to practical solutions in resource-limited settings. Stop TB Partnership participated in the session as a program partner.

MEDICAL IP develops medical imaging AI that quantifies anatomical information and transforms it into digital twins. Building on its experience applying imaging technology to pneumonia analysis during the COVID-19 pandemic, the company is extending its work across areas including cancer, cardiovascular disease, and tuberculosis.

DeepCatch X analyzes chest X-rays to quantify anatomical structures and disease-related information. DeepCatch X TB provides a score indicating the level of suspicion for active pulmonary tuberculosis and quantifies the location and extent of relevant findings. This information can support healthcare professionals in identifying individuals who may need further testing and in reviewing changes across follow-up images.

MEDICAL IP aims to work with global partners to bring medical AI into real-world health programs and help broaden access to screening and monitoring.